Combivir Tab 60 S100 (Lamivudine Zidovudine Tab)
Combivir Tab 60 S100, containing the active ingredients Lamivudine and Zidovudine, is a scientifically formulated antiretroviral medication designed to inhibit the replication of the Human Immunodeficiency Virus (HIV). This combination therapy is a cornerstone in the management of HIV infection and is used as part of Highly Active Antiretroviral Therapy (HAART).
Technical Specifications:
- Composition: Each tablet contains Lamivudine (150 mg) and Zidovudine (300 mg)
- Formulation: Oral tablets
- Packaging: 60 tablets per bottle (S100)
- Storage: Store at room temperature away from moisture and heat
- Administration: Twice daily oral administration, with or without food
Common Applications:
- HIV-1 Infection: Indicated for the treatment of HIV-1 infected adults and children
- Post-Exposure Prophylaxis: May be used in certain cases following potential HIV exposure
User Groups:
- Adults and children with confirmed HIV-1 infection
- Healthcare professionals managing patients requiring antiretroviral therapy
- Individuals seeking post-exposure prophylaxis after potential HIV exposure
Supplier Overview:
ViiV Healthcare is a global specialist HIV company established by GlaxoSmithKline and Pfizer, with Shionogi joining later, to deliver advances in treatment and care for people living with HIV. As a leader in the field of HIV/AIDS, ViiV Healthcare is committed to addressing the unmet needs of those affected by this virus. Their authority in the product category is underpinned by their dedication to innovative research, their extensive portfolio of antiretroviral drugs, and their active involvement in the HIV community. With a focus solely on HIV, ViiV Healthcare's expertise ensures that products like Combivir Tab 60 S100 are developed and provided with the highest standards of efficacy and safety in mind.
